

FOI 2075 –Approval dates for each approved indication for Risperdal (risperidone)

Approval Date	Indication
30/11/1993	Risperdal is indicated for the treatment of schizophrenia.
14/01/1998	RISPERDAL is indicated for the treatment of schizophrenia and related psychoses
21/12/1999	RISPERDAL is indicated for the treatment of behavioural and psychological symptoms of dementia such as aggressiveness (verbal outbursts, physical violence), activity disturbances (agitation, wandering) or psychotic symptoms"
13/09/2002	treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent.
27/10/2004	the short term treatment of acute mania associated with bipolar 1 disorder.
30/03/2005	the treatment of behavioural disorders associated with autism in children and adolescents

Current indication as per ARTG:

RISPERDAL is indicated for the treatment of schizophrenia and related psychoses.

RISPERDAL is indicated for the short term treatment of acute mania associated with bipolar 1 disorder.

RISPERDAL is also indicated for the treatment of behavioural disturbances in dementia.

RISPERDAL is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see Clinical Trials for maintenance data).

RISPERDAL is indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see Clinical Trials).